Back to Search
Start Over
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate
- Source :
- AIDS Research and Human Retroviruses. 38:939-943
- Publication Year :
- 2022
- Publisher :
- Mary Ann Liebert Inc, 2022.
-
Abstract
- Transgender persons have an increased vulnerability to HIV infection yet have not been well-represented in past clinical trials for pre-exposure prophylaxis (PrEP). Because of this, there are few data available to understand whether gender-affirming hormone concentrations are influenced by PrEP agents in transgender men (TM) and transgender women (TW). The objective of this study was to compare gender-affirming hormone concentrations with versus without emtricitabine (F, FTC)-tenofovir disoproxil fumarate (TDF). TM and TW without HIV, aged 15-24 years, were enrolled for 1 month of directly observed daily F/TDF. Participants were required to be receiving a stable hormone dose (estradiol or testosterone) for at least 1 month or three consecutive doses, whichever was longer, before enrollment and willing to continue the same dose. Intensive pharmacokinetic (PK) sampling for gender-affirming hormones was collected before and 2-3 weeks after daily F/TDF. Serum estradiol and total testosterone were determined by liquid chromatography-tandem mass spectrometry; free testosterone by equilibrium dialysis. Maximum concentrations (C
- Subjects :
- Infectious Diseases
Virology
Immunology
Subjects
Details
- ISSN :
- 19318405 and 08892229
- Volume :
- 38
- Database :
- OpenAIRE
- Journal :
- AIDS Research and Human Retroviruses
- Accession number :
- edsair.doi.dedup.....1c9b2ee78aff3edfd2894532792aa7c0